Drug-Eluting Stents: Revolution In Patient Care Or Excessive Euphoria?
This article was originally published in The Gray Sheet
Executive Summary
Intravascular ultrasound (IVUS) and angiography, used in recent pivotal trials of drug-eluting stents, cannot accurately predict the long term effects of the devices, according to Renu Virmani, MD, Armed Forces Institute of Pathology
You may also be interested in...
Anti-Restenosis Alternative Envisioned By Biodegradable Stent Developers
Biodegradable stent R&D will accelerate as long-term efficacy data on drug-eluting stents becomes available, several presenters predicted at the Cardiovascular Revascularization Therapy conference in Washington, D.C. Jan. 26-29
Anti-Restenosis Alternative Envisioned By Biodegradable Stent Developers
Biodegradable stent R&D will accelerate as long-term efficacy data on drug-eluting stents becomes available, several presenters predicted at the Cardiovascular Revascularization Therapy conference in Washington, D.C. Jan. 26-29
FDA Panel Review Of J&J Cypher Stent Will Weigh SIRIUS Late Loss Data
Johnson & Johnson/Cordis' upcoming presentation before an FDA advisory panel on the Cypher drug-eluting stent will highlight a 67% reduction of target vessel failure (TVF) at nine months compared with bare stents